Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(158 produtos)
- Bcr-Abl(113 produtos)
- EGFR(598 produtos)
- FAK(72 produtos)
- FLT(90 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(182 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(53 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2040 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Fórmula:C26H22F2N6O4SPureza:98.87%Cor e Forma:SolidPeso molecular:552.55KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Fórmula:C26H30FN7OPureza:98.49% - >99.99%Cor e Forma:SolidPeso molecular:475.56Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Fórmula:C24H25ClN4O5Pureza:99.81%Cor e Forma:SolidPeso molecular:484.93IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Fórmula:C25H20N6OPureza:99.79%Cor e Forma:SolidPeso molecular:420.47Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Fórmula:C28H28F4N6O4Pureza:98.84% - 99.85%Cor e Forma:SolidPeso molecular:588.55Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Fórmula:C34H32ClFN8O4Pureza:98.35%Cor e Forma:SolidPeso molecular:671.12HM43239
CAS:HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.Fórmula:C29H33ClN6Pureza:99.7%Cor e Forma:SolidPeso molecular:501.07Tyrosine kinase-IN-9
CAS:<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Fórmula:C20H14ClN3O3Cor e Forma:SolidPeso molecular:379.796TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Fórmula:C21H21NO4Cor e Forma:SolidPeso molecular:351.396lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Fórmula:C16H25N5OSCor e Forma:SolidPeso molecular:335.468LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Fórmula:C26H31N7O2Cor e Forma:SolidPeso molecular:473.57EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Fórmula:C13H13N5OCor e Forma:SolidPeso molecular:255.275VEGFR-2-IN-65
CAS:VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.Fórmula:C21H18N2O3Cor e Forma:SolidPeso molecular:346.379Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Fórmula:C20H20N4O2SCor e Forma:SolidPeso molecular:380.463DA-0157
CAS:<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Fórmula:C31H43BrN7O2PCor e Forma:SolidPeso molecular:656.597FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Fórmula:C16H9N5O3SCor e Forma:SolidPeso molecular:351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Fórmula:C28H28N6O4Cor e Forma:SolidPeso molecular:512.56FGFR4-IN-7
FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.Fórmula:C26H25Cl2N5O3Cor e Forma:SolidPeso molecular:526.41VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Fórmula:C24H18N6O2SCor e Forma:SolidPeso molecular:454.5EGFR-IN-44
EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.Fórmula:C27H29ClN6O2SCor e Forma:SolidPeso molecular:537.08
